New cardiovascular risk calculator now available online
NEW YORK — In line with American Heart Month, Boehringer Ingelheim’s Micardis has introduced a cardiovascular risk-reduction calculator, designed to assess patients’ cardiovascular risk.
The calculator, which can be accessed at MicardisPro.com, is an interactive, useful tool for healthcare professionals to assist patients in reaching their cardiovascular risk-reduction goal, the company said.
Micardis (telmisartan) is a drug designed to treat hypertension.
Hi-Tech Pharmacal receives market exclusivity for generic Neurontin
AMITYVILLE, N.Y. — Generic drug maker Hi-Tech Pharmacal has received Food and Drug Administration approval for its version of a drug used to treat neurological disorders, the company said Tuesday.
Hi-Tech announced the approval of gabapentin oral solution in the 250 mg/5 mL strength, a generic version of Pfizer’s Neurontin oral solution.
The drug is used to treat postherpetic neuralgia and epilepsy. Neurontin had sales of $15 million in 2010, according to IMS Health.
As the first company to file for generic approval, Hi-Tech will get 180 days in which to compete directly with the branded version.
BioScrip utilizes HealthyCircles platform for website
ELMSFORD, N.Y. — Specialty pharmacy provider BioScrip has launched a Web service designed to connect healthcare professionals, patients and caregivers in order to help patients manage their medications and improve their overall care experience.
The website, myBioScrip.com, uses HealthyCircles, an online platform that enables people to use manage and share health information.
“We believe the HealthyCircles platform will enable BioScrip to define the future of specialty pharmacy and home infusion by enabling physicians, patients, family caregivers and pharmacists to securely connect with each other and manage care using a robust, permission-based framework,” BioScrip president and CEO Rick Smith stated. “It’s time we created a patient-centric model in the specialty space, and BioScrip is proud to be the first.”